HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) CME: Take the course for this article: Volume 56, Number 6, March 27, 2001 Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Veldink, J.H. Articles by Scheffer, H. Search for Related Content PubMed PubMed Citation Articles by Veldink, J.H. Articles by Scheffer, H.

Homozygous deletion of the survival motor neuron 2 gene is a prognostic factor in sporadic ALS

From the Department of Neurology (Drs. Veldink, van den Berg, and Wokke), University Medical Center Utrecht; The Department of Medical Genetics (Dr. Cobben), Free University Amsterdam; The Department of Medical Genetics (Dr. Scheffer and R.P. Stulp), University of Groningen; The Department of Neurology (Drs. De Jong and Baas), Amsterdam Medical Center, and The Department of Neurology (Dr. Vogels), University Hospital Nijmegen, The Netherlands.

Address correspondence and reprint requests to Dr. L.H. van den Berg, Department of Neurology, G.03.228, University Medical Center Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands; e-mail: l.h.vandenberg{at}neuro.azu.nl

BACKGROUND: Spinal muscular atrophy (SMA) results from mutations of the survival motor neuron (SMN) gene on chromosome 5. The SMN gene exists in two highly homologous copies, telomeric (SMN1) and centromeric (SMN2). SMA is caused by mutations in SMN1 but not SMN2. The clinical phenotype of SMA appears to be related to the expression of SMN2. Patients suffering from the milder forms of SMA carry more copies of the SMN2 gene compared with patients with more severe SMA. It is suggested that the SMN2 gene is translated into an at least partially functional protein that protects against loss of motor neurons.

OBJECTIVE: To investigate whether genetic mechanisms implicated in motor neuron death in SMA have a role in ALS.

METHODS: The presence of deletions of exons 7 and 8 of SMN1 and SMN2 was determined in 110 patients with sporadic ALS and compared with 100 unaffected controls.

RESULTS: The presence of a homozygous SMN2 deletion was overrepresented in patients with ALS compared with controls (16% versus 4%; OR, 4.4; 95% CI, 1.4 to 13.5). Patients with a homozygous SMN2 deletion had a shorter median time of survival (p < 0.009). Furthermore, multivariate regression analysis showed that the presence of an SMN2 deletion was independently associated with survival time (p < 0.02). No homozygous deletions in SMN1 were found. Carrier status of SMA appeared to be equally present in patients and controls (1 in 20).

CONCLUSION: These results indicate that, similar to SMA, the SMN2 gene can act as a prognostic factor and may therefore be a phenotypic modifier in sporadic ALS. Increasing the expression of the SMN2 gene may provide a strategy for treatment of motor neuron disease.

This article has been cited by other articles:

				J. E. Landers, J. Melki, V. Meininger, J. D. Glass, L. H. van den Berg, M. A. van Es, P. C. Sapp, P. W. J. van Vught, D. M. McKenna-Yasek, H. M. Blauw, et al. Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis PNAS, June 2, 2009; 106(22): 9004 - 9009. [Abstract] [Full Text] [PDF]

				S. Cronin, H. M. Blauw, J. H. Veldink, M. A. van Es, R. A. Ophoff, D. G. Bradley, L. H. van den Berg, and O. Hardiman Analysis of genome-wide copy number variation in Irish and Dutch ALS populations Hum. Mol. Genet., November 1, 2008; 17(21): 3392 - 3398. [Abstract] [Full Text] [PDF]

				J.C. Schymick, K. Talbot, and B.J. Traynor Genetics of sporadic amyotrophic lateral sclerosis Hum. Mol. Genet., October 15, 2007; 16(R2): R233 - R242. [Abstract] [Full Text] [PDF]

				L. Regal, L. Vanopdenbosch, P. Tilkin, L. Van Den Bosch, V. Thijs, R. Sciot, and W. Robberecht The G93C Mutation in Superoxide Dismutase 1: Clinicopathologic Phenotype and Prognosis Arch Neurol, February 1, 2006; 63(2): 262 - 267. [Abstract] [Full Text] [PDF]

				P J Shaw Molecular and cellular pathways of neurodegeneration in motor neurone disease J. Neurol. Neurosurg. Psychiatry, August 1, 2005; 76(8): 1046 - 1057. [Abstract] [Full Text] [PDF]

				C. Munch, R. Sedlmeier, T. Meyer, V. Homberg, A. D. Sperfeld, A. Kurt, J. Prudlo, G. Peraus, C. O. Hanemann, G. Stumm, et al. Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS Neurology, August 24, 2004; 63(4): 724 - 726. [Abstract] [Full Text] [PDF]

				T. Meyer, B. Alber, K. Roemer, T. Martin, V.M. Kalscheuer, E. Gottert, K.D. Zang, A.C. Ludolph, H.-H. Ropers, and J. Prudlo High rate of constitutional chromosomal rearrangements in apparently sporadic ALS Neurology, April 22, 2003; 60(8): 1348 - 1350. [Abstract] [Full Text] [PDF]

				J. Gamez, M. J. Barcelo, X. Munoz, F. Carmona, I. Cusco, M. Baiget, C. Cervera, and E.F. Tizzano Survival and respiratory decline are not related to homozygous SMN2 deletions in ALS patients Neurology, November 12, 2002; 59(9): 1456 - 1460. [Abstract] [Full Text] [PDF]

				R. Rojas-Garcia, E. Tizzano, I. Cusco, E. Gallardo, M. J. Barcelo, I. de Andres, P. Larrode, J. F. Marti-Masso, J. A. Martinez-Matos, M. Povedano, et al. The absence of survival motor neuron 2 gene may play a role in multifocal motor neuropathy Neurology, October 8, 2002; 59(7): 1112 - 1113. [Full Text] [PDF]